Navigating 8 Analyst Ratings For Y-mAbs Therapeutics | Nasdaq

Sep 9, 2024 · Y-mAbs Therapeutics (NASDAQ:YMAB) underwent analysis by 8 analysts in the last quarter, ... Navigating 8 Analyst Ratings For Y-mAbs Therapeutics September 09, 2024 — …

$7.39
OFF

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus …

2 weeks from now

6 days ago · Y-mAbs Therapeutics stock opened at $7.39 on Friday. Y-mAbs Therapeutics has a 52 week low of $6.92 and a 52 week high of $20.90. The firm has a market cap of $330.99 …

etfdailynews.com

$26.00
OFF

Y-Mabs Therapeutics: Promising Pipeline Developments And …

2 weeks from now

Nov 11, 2024 · Canaccord Genuity analyst John Newman maintained a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) on November 8 and set a price target of $26.00.. …

businessinsider.com

$0.16
OFF

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus ...

2 weeks from now

Dec 16, 2024 · Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Friday, November 8th.The company reported ($0.16) EPS for the …

marketbeat.com

0%
OFF

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average

2 weeks from now

6 days ago · Bank of New York Mellon Corp increased its holdings in shares of Y-mAbs Therapeutics by 8.0% in the second quarter. Bank of New York Mellon Corp now owns …

marketbeat.com

$9.77
OFF

HC Wainwright Reaffirms “Buy” Rating For Y-mAbs Therapeutics …

2 weeks from now

Dec 13, 2024 · YMAB opened at $9.77 on Wednesday. The firm has a market cap of $437.60 million, a P/E ratio of -18.09 and a beta of 0.61. Y-mAbs Therapeutics has a 1-year low of …

etfdailynews.com

$6.33
OFF

HC Wainwright Reaffirms Buy Rating For Y-mAbs Therapeutics …

2 weeks from now

1 day ago · Shares of YMAB opened at $6.33 on Monday. The company has a market capitalization of $283.51 million, a P/E ratio of -11.72 and a beta of 0.69. Y-mAbs Therapeutics …

etfdailynews.com

$22.00
OFF

Y-Mabs Therapeutics (YMAB) Receives A Buy From H.C. Wainwright

2 weeks from now

3 days ago · H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) on January 10 and set a price target of $22.00.The …

businessinsider.com

$23
OFF

Y MAbs Therapeutics : Company Presentation - January

2 weeks from now

2 days ago · Oppenheimer Initiates Coverage on Y-mAbs Therapeutics With Outperform Rating, $23 Price Target Nov. 18: MT Y-mAbs Therapeutics, Inc., Q3 2024 Earnings Call, Nov 08, …

marketscreener.com

$6.89
OFF

HC Wainwright Reiterates Buy Rating For Y-mAbs ... - MarketBeat

2 weeks from now

3 days ago · Check Out Our Latest Stock Report on Y-mAbs Therapeutics Y-mAbs Therapeutics Trading Down 6.8 %. YMAB opened at $6.89 on Monday. Y-mAbs Therapeutics has a 12 …

marketbeat.com

$331
OFF

Y-mAbs Therapeutics Announces Strategic Business Realignment

2 weeks from now

5 days ago · The latest update is out from Y-Mabs Therapeutics ( (YMAB) ). ... Technical Sentiment Consensus Rating: Buy. Current Market Cap: $331M. Learn more about YMAB …

yahoo.com

$6.33
OFF

Barclays PLC Raises Holdings In Y-mAbs Therapeutics ... - ETF Daily …

2 weeks from now

1 day ago · Y-mAbs Therapeutics Price Performance. Shares of YMAB stock opened at $6.33 on Wednesday. The business’s fifty day moving average price is $10.15 and its 200 day moving …

etfdailynews.com

FAQs about Navigating 8 Analyst Ratings For Y-mAbs Therapeutics | Nasdaq Coupon?

Should you buy y-mAbs Therapeutics (ymab)?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has earned a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. ...

Will y-mAbs Therapeutics (ymab) post -0.66 EPs?

On average, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current fiscal year. A number of large investors have recently made changes to their positions in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics in the third quarter valued at about $44,000. ...

Will HC Wainwright reissue a 'Buy' rating on Y-mAbs Therapeutics?

HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. ...

Who owns y-mAbs Therapeutics?

China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after buying an additional 3,416 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. ...

Which large investors have changed their positions in ymab?

A number of large investors have recently made changes to their positions in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics in the third quarter valued at about $44,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Y-mAbs Therapeutics by 66.3% in the third quarter. ...

Why did Michael Ulz give y-MABS a sell rating?

Michael Ulz has given his Sell rating due to a combination of factors pertaining to Y-Mabs Therapeutics’ current situation and future prospects. The company’s FY24 product sales are in line with expectations but only at the low end of their guidance range, indicating limited immediate growth potential. ...